serw-MX  [xml]  
 


    
 DeCS Categories

C05 Musculoskeletal Diseases .
C05.660 Musculoskeletal Abnormalities .
C05.660.207 Craniofacial Abnormalities .
C05.660.207.690 Noonan Syndrome .
C14 Cardiovascular Diseases .
C14.240 Cardiovascular Abnormalities .
C14.240.400 Heart Defects, Congenital .
C14.240.400.787 Noonan Syndrome .
C14.280 Heart Diseases .
C14.280.400 Heart Defects, Congenital .
C14.280.400.787 Noonan Syndrome .
C16 Congenital, Hereditary, and Neonatal Diseases and Abnormalities .
C16.131 Congenital Abnormalities .
C16.131.240 Cardiovascular Abnormalities .
C16.131.240.400 Heart Defects, Congenital .
C16.131.240.400.784 Noonan Syndrome .
C16.131.621 Musculoskeletal Abnormalities .
C16.131.621.207 Craniofacial Abnormalities .
C16.131.621.207.690 Noonan Syndrome .
C17 Skin and Connective Tissue Diseases .
C17.300 Connective Tissue Diseases .
C17.300.690 Noonan Syndrome .
D02 Organic Chemicals .
D02.065 Amides .
D02.065.064 Acetamides .
D02.065.064.650 Piracetam .
D02.241 Carboxylic Acids .
D02.241.081 Acids, Acyclic .
D02.241.081.018 Acetates .
D02.241.081.018.110 Acetamides .
D02.241.081.018.110.650 Piracetam .
D03 Heterocyclic Compounds .
D03.383 Heterocyclic Compounds, 1-Ring .
D03.383.773 Pyrrolidines .
D03.383.773.812 Pyrrolidinones .
D03.383.773.812.555 Piracetam .
D27 Chemical Actions and Uses .
D27.505 Pharmacologic Actions .
D27.505.954 Therapeutic Uses .
D27.505.954.427 Central Nervous System Agents .
D27.505.954.427.637 Nootropic Agents .
 
 Terms
 Synonyms & Historicals
Documents
LILACS e MDL
 
Piracetam .
2-Pyrrolidone-N-Acetamide .
Avigilen .
Axonyl .
Cerebroforte .
Cerepar N .
Ciclofalina .
Cuxabrain .
Dinagen .
Gabacet .
Geram .
Memo-Puren .
Nootrop .
Nootropil .
Nootropyl .
Normabraïn .
Piracebral .
Piracetam AbZ .
Piracetam-RPh .
Piracetrop .
Pirazetam .
Pyracetam .
Pyramem .
Sinapsan .
UCB-6215 .
Memo Puren .
Piracetam RPh .
UCB 6215 .
UCB6215 .
A compound suggested to be both a nootropic and a neuroprotective agent. .
1.00
212987
 
Nootropic Agents .
Nootropic Drugs .
Nootropics .
Agents, Nootropic .
Drugs, Nootropic .
Enhancers, Cognitive .
Cognitive Enhancers .
Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated. .
0.88
264249
 
Noonan Syndrome .
Familial Turner Syndrome .
Female Pseudo-Turner Syndrome .
Noonan Syndrome 1 .
Noonan-Ehmke Syndrome .
Pseudo-Ullrich-Turner Syndrome .
Turner Phenotype with Normal Karyotype .
Turner's Phenotype, Karyotype Normal .
Turner's Syndrome, Male .
Turner-Like Syndrome .
Ullrich-Noonan Syndrome .
Female Pseudo Turner Syndrome .
Male Turner's Syndrome .
Noonan Ehmke Syndrome .
Pseudo Ullrich Turner Syndrome .
Pseudo-Turner Syndrome, Female .
Syndrome, Familial Turner .
Syndrome, Female Pseudo-Turner .
Syndrome, Male Turner .
Syndrome, Male Turner's .
Syndrome, Noonan .
Syndrome, Noonan-Ehmke .
Syndrome, Pseudo-Ullrich-Turner .
Syndrome, Turner-Like .
Syndrome, Ullrich-Noonan .
Turner Like Syndrome .
Turner Syndrome, Familial .
Ullrich Noonan Syndrome .
Turner Syndrome, Male .
Male Turner Syndrome .
TURNER'S SYNDROME, MALE .
A genetically heterogeneous, multifaceted disorder characterized by short stature, webbed neck, ptosis, skeletal malformations, hypertelorism, hormonal imbalance, CRYPTORCHIDISM, multiple cardiac abnormalities (most commonly including PULMONARY VALVE STENOSIS), and some degree of INTELLECTUAL DISABILITY. The phenotype bears similarities to that of TURNER SYNDROME that occurs only in females and has its basis in a 45, X karyotype abnormality. Noonan syndrome occurs in both males and females with a normal karyotype (46,XX and 46,XY). Mutations in a several genes (PTPN11, KRAS, SOS1, NF1 and RAF1) have been associated the the NS phenotype. Mutations in PTPN11 are the most common. LEOPARD SYNDROME, a disorder that has clinical features overlapping those of Noonan Syndrome, is also due to mutations in PTPN11. In addition, there is overlap with the syndrome called neurofibromatosis-Noonan syndrome due to mutations in NF1. .
0.47
551404